<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04736810</url>
  </required_header>
  <id_info>
    <org_study_id>AK105-205</org_study_id>
    <nct_id>NCT04736810</nct_id>
  </id_info>
  <brief_title>A Study of Penpulimab Combination Therapy in Patients With Advanced Nasopharyngeal Carcinoma</brief_title>
  <official_title>A Phase II Study of Penpulimab Combined With Chemotherapy ± Anlotinib Hydrochloride in Patients With Advanced Nasopharyngeal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Akeso</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Akeso Tiancheng, Inc</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Akeso</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, randomized, open-label, phase II study to evaluate the efficacy and&#xD;
      safety of anti-PD-1 antibody Penpulimab (AK105) combined with chemotherapy ± anlotinib&#xD;
      hydrochloride in the first-line treatment of patients with advanced nasopharyngeal carcinoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">February 2021</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>up to 2 years</time_frame>
    <description>ORR is the proportion of subjects with CR or PR based on RECIST v1.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>up to 2 years</time_frame>
    <description>PFS is defined as the time from the date of randomization till the first documentation of disease progression (per RECIST v1.1 criteria) or death from any cause (whichever occurs first).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>up to 2 years</time_frame>
    <description>DCR is defined as the proportion of subjects with CR, PR, or SD, based on RECIST v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DoR)</measure>
    <time_frame>up to 2 years</time_frame>
    <description>DoR is defined as the duration from the first documentation of objective response to the first documented disease progression or death due to any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>up to 2 years</time_frame>
    <description>OS is defined as the time from the date of randomization to death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed concentrations of AK105</measure>
    <time_frame>From first dose of AK105 through 90 days after last dose of AK105.</time_frame>
    <description>The endpoints for assessment of PK of AK105 include serum concentrations of AK105 at different timepoints after AK105 administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects who develop detectable anti-drug antibodies (ADAs)</measure>
    <time_frame>From first dose of AK105 through 90 days after last dose of AK105.</time_frame>
    <description>The immunogenicity of AK105 will be assessed by summarizing the number of subjects who develop detectable antidrug antibodies (ADAs).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>AK105 plus Cisplatin, Gemcitabine and Anlotinib Hydrochloride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AK105 plus Cisplatin and Gemcitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AK105 plus Gemcitabine and Anlotinib Hydrochloride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AK105</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>AK105 plus Cisplatin and Gemcitabine</arm_group_label>
    <arm_group_label>AK105 plus Cisplatin, Gemcitabine and Anlotinib Hydrochloride</arm_group_label>
    <arm_group_label>AK105 plus Gemcitabine and Anlotinib Hydrochloride</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>AK105 plus Cisplatin and Gemcitabine</arm_group_label>
    <arm_group_label>AK105 plus Cisplatin, Gemcitabine and Anlotinib Hydrochloride</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>AK105 plus Cisplatin and Gemcitabine</arm_group_label>
    <arm_group_label>AK105 plus Cisplatin, Gemcitabine and Anlotinib Hydrochloride</arm_group_label>
    <arm_group_label>AK105 plus Gemcitabine and Anlotinib Hydrochloride</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anlotinib hydrochloride</intervention_name>
    <description>Oral administration</description>
    <arm_group_label>AK105 plus Cisplatin, Gemcitabine and Anlotinib Hydrochloride</arm_group_label>
    <arm_group_label>AK105 plus Gemcitabine and Anlotinib Hydrochloride</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed written informed consent form voluntarily.&#xD;
&#xD;
          -  Age over 18 years old (inclusive) and not more than 75 years old (inclusive), when&#xD;
             signing the ICF.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance score 0 or 1.&#xD;
&#xD;
          -  Expected life expectance ≥ 3 months.&#xD;
&#xD;
          -  Histologically confirmed diagnosis of stage IVb NPC (AJCC 8th).&#xD;
&#xD;
          -  Metastatic NPC patients who have not recieved the first-line platinumbased&#xD;
             chemotherapy.&#xD;
&#xD;
          -  At least one measurable tumor lesion per RECIST 1.1 criteria.&#xD;
&#xD;
          -  Subjects must provide an available tumor tissue sample taken within 3 years prior to&#xD;
             enrollment.&#xD;
&#xD;
          -  Adequate organ function.&#xD;
&#xD;
          -  Females of childbearing potential who are sexually active with a nonsterilized male&#xD;
             partner must use at least one highly effective method of contraception.&#xD;
&#xD;
          -  Nonsterilized males who are sexually active with a female partner of childbearing&#xD;
             potential must use highly effective method of contraception from Day 1 and for 120&#xD;
             days after the last dose of investigational product.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other invasive malignancies within 2 years, except for locally treatable (manifested&#xD;
             as cured) malignancies, such as basal or skin squamous cell carcinoma, superficial&#xD;
             bladder cancer, cervical or breast carcinoma in situ.&#xD;
&#xD;
          -  Is currently participating in a study of an investigational agent or using an&#xD;
             investigational device.&#xD;
&#xD;
          -  Has known active central nervous system (CNS) metastases.&#xD;
&#xD;
          -  Has an active autoimmune disease that has required systemic treatment in the past 2&#xD;
             years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive&#xD;
             drugs). Replacement therapy (e.g., thyroxine, insulin or physiologic corticosteroid&#xD;
             replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a&#xD;
             form of systemic treatment NOTE: Subjects with vitiligo or resolved childhood&#xD;
             asthma/atopy would be an exception to this rule. Subjects that require intermittent&#xD;
             use of bronchodilators or local steroid injections would not be excluded from the&#xD;
             study.&#xD;
&#xD;
          -  Has an active infection requiring systemic therapy.&#xD;
&#xD;
          -  Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA&#xD;
             [qualitative] is detected).&#xD;
&#xD;
          -  History of myocardial infarction, unstable angina, cardiac or other vascular stenting,&#xD;
             angioplasty, or surgery within 12 months prior to day 1 of study treatment.&#xD;
&#xD;
          -  Has undergone major surgery within 30 days of Study Day 1.&#xD;
&#xD;
          -  Has received a live virus vaccine within 30 days of the planned first dose of study&#xD;
             therapy.&#xD;
&#xD;
          -  Has known psychiatric or substance abuse disorders that would interfere with&#xD;
             cooperation with the requirements of the study.&#xD;
&#xD;
          -  Is pregnant, breastfeeding, or expecting to conceive or father a child within the&#xD;
             projected duration of the study including 120 days following the last dose of study&#xD;
             treatment.&#xD;
&#xD;
          -  Has a history or current evidence of any condition, therapy, or laboratory abnormality&#xD;
             that might confound the results of the study, interfere with the subject's&#xD;
             participation for the full duration of the study, or is not in the best interest of&#xD;
             this subject to participate, in the opinion of the treating investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaozhong Chen, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cancer Hospital of The University of Chinese Academy of Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Weifeng Song, MD</last_name>
    <phone>+86(0760)89873999</phone>
    <email>clinicaltrials@akesobio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cancer Hospital of the University of Chinese Academy of Sciences</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaozhong Chen, MD</last_name>
      <phone>+86(0571)88122222</phone>
      <email>cxzfyun@sina.com</email>
    </contact>
    <investigator>
      <last_name>Xiaozhong Chen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 30, 2021</study_first_submitted>
  <study_first_submitted_qc>January 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 3, 2021</study_first_posted>
  <last_update_submitted>January 30, 2021</last_update_submitted>
  <last_update_submitted_qc>January 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immunotherapy</keyword>
  <keyword>Anti-PD-1 antibody</keyword>
  <keyword>Nasopharyngeal Carcinoma</keyword>
  <keyword>VEGF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

